Tomohiko Sato,Kenichi Yoshida,Tsutomu Toki,Rika Kanezaki,Kiminori Terui,Ryunosuke Saiki,Masami Ojima,Yotaro Ochi,Seiya Mizuno,Masaharu Yoshihara,Tamayo Uechi,Naoya Kenmochi,Shiro Tanaka,Jun Matsubayashi,Kenta Kisai,Ko Kudo,Kentaro Yuzawa,Yuka Takahashi,Tatsuhiko Tanaka,Yohei Yamamoto,Akie Kobayashi,Takuya Kamio,Shinya Sasaki,Yuichi Shiraishi,Kenichi Chiba,Hiroko Tanaka,Hideki Muramatsu,Asahito Hama,Daisuke Hasegawa,Atsushi Sato,Katsuyoshi Koh,Shuhei Karakawa,Masao Kobayashi,Junichi Hara,Yuichi Taneyama,Chihaya Imai,Daiichiro Hasegawa,Naoto Fujita,Masahiro Yoshitomi,Shotaro Iwamoto,Genki Yamato,Satoshi Saida,Nobutaka Kiyokawa,Takao Deguchi,Masafumi Ito,Hidemasa Matsuo,Souichi Adachi,Yasuhide Hayashi,Takashi Taga,Akiko Moriya Saito,Keizo Horibe,Kenichiro Watanabe,Daisuke Tomizawa,Satoru Miyano,Satoru Takahashi,Seishi Ogawa,Etsuro Ito

Abstract:Transient abnormal myelopoiesis (TAM) is a common complication in newborns with Down syndrome (DS). It commonly progresses to myeloid leukemia (ML-DS) after spontaneous regression. In contrast to the favorable prognosis of primary ML-DS, patients with refractory/relapsed ML-DS have poor outcomes. However, the molecular basis for refractoriness and relapse, and the full spectrum of driver mutations in ML-DS remain largely unknown. We conducted a genomic profiling study of 143 TAM, 204 ML-DS, and...

Landscape of driver mutations and their clinical effects on Down syndrome-related myeloid neoplasms